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Background: Malaria rapid diagnostic tests (RDTs) are a useful tool in endemic malaria countries, where light
microscopy is not feasible. In non-endemic countries they can be used as complementary tests to provide timely
results in case of microscopy inexperience. This study aims to compare the new VIKIA Malaria Ag Pf/Pan™ RDT with
PCR-corrected microscopy results and the commonly used CareStart™ RDT to diagnose falciparum and
non-falciparum malaria in the endemic setting of Bamako, Mali and the non-endemic setting of Lyon, France.
Methods: Blood samples were collected during a 12-months and six-months period in 2011 from patients
suspected to have malaria in Lyon and Bamako respectively. The samples were examined by light microscopy, the
VIKIA Malaria Ag Pf/Pan™ test and in Bamako additionally with the CareStart™ RDT. Discordant results were
corrected by real-time PCR. Sensitivity, specificity, positive predictive value and negative predictive value were used
to evaluate test performance.
Results: Samples of 877 patients from both sites were included. The VIKIA Malaria Ag Pf/Pan™ had a sensitivity of
98% and 96% for Plasmodium falciparum in Lyon and Bamako, respectively, performing similar to PCR-corrected
microscopy.
Conclusions: The VIKIA Malaria Ag Pf/Pan™ performs similar to PCR-corrected microscopy for the detection of P.
falciparum, making it a valuable tool in malaria endemic and non-endemic regions.
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Malaria diagnostic plays a key role in malaria control and
elimination programmes in order to avoid unnecessary
anti-malarial therapy, to prevent drug resistance and to
enhance case finding. The World Health Organization
(WHO) estimated that in the African region, approxi-
mately one half of suspected malaria cases received para-
sitological confirmation [1]. The number of courses of
artemisinin combination therapy (ACT) still exceeds the
total number of malaria diagnostic tests by a factor of 2,
indicating that many patients receive ACT without
confirmatory diagnosis [1]. The Test-Treat-Track (T3)* Correspondence: daniel.eibach@chu-lyon.fr
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reproduction in any medium, provided the orinitiative, recently launched by the WHO, is a clear indica-
tion that malaria management should be based on evi-
dences. It is well documented that treatment based on
symptoms results in overtreatment of patients who do not
suffer from malaria [2]. Although clinical diagnosis is im-
precise, it remains the basis of therapeutic care for too
many febrile patients in malaria endemic areas, where la-
boratory support is often out of reach or negative slide
results are disregarded. As a consequence, serious non-
malarial infections are missed, drugs are wasted, resistance
is increasing, and the cost effectiveness of the diagnostic
tests is reduced [3-5].
The commonly accepted gold standard diagnostic
method for detecting malaria was, for decades, micro-
scopic reading of Giemsa-stained thick and thin blood
films. Microscopy constrains in malaria endemic regionsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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quality reagents and well-maintained microscopes as
well as its time consumption [6]. Even in developed and
non-endemic countries, expert malaria microscopists are
scarce and impaired microscopy-based diagnosis, espe-
cially for non-falciparum species, in hospital laboratories
is common [7-9]. Most laboratories in non-endemic coun-
tries lack sufficient samples to build-up and maintain
microscopic expertise.
Malaria rapid diagnostic tests (RDTs) are an alternative
diagnostic method for endemic regions, where microscopy
has not been implemented, as well as for non-endemic
countries, where they are able complement microscopy in
screening febrile travellers. The first commercial RDT was
marketed in 1994, and more than 200 devices from more
than 60 manufacturers are now available in the world
market. Some of them were successfully evaluated by
international organizations [10-12]. Several of these RDTs
showed high efficiency for the diagnosis of malaria in dif-
ferent conditions. One of the drawbacks of these devices
is the quality of tests compared to microscopy and their
practicability for local staff in remote areas [13]. In order
to evaluate the performance of a new device, the VIKIA
Malaria Ag Pf/Pan™ RDT, a prospective study was
conducted both in an endemic area (Bamako, Mali) and a
non-endemic area (Lyon, France). This RDT was during
the same period, evaluated in field condition by members
of the anti-malarial drug-resistance network in Cambodia
[14] and showed good performances. The secondary
objective of the study was to compare data obtained
from technicians working in a general health care
centre located in an endemic area, daily exposed to a
high number of malaria diagnosis, to those obtained by
technicians from an European University Hospital where
malaria is restricted to two imported case per week, on a
yearly basis mean. The sensitivity and specificity of VIKIA
Malaria Ag Pf/Pan™ were compared with PCR-corrected
microscopy results and the commonly used CareStart™
RDT in Bamako. Both RDTs are detecting falciparum and
non-falciparum malaria. The VIKIA Malaria Ag Pf/Pan™ is
using HRP2/Aldolase antigens while the CareStart™ is
using HRP2/pLDH antigens.
Methods
Study design in Lyon
The first part of the study was performed during a 12-
months period from January to December 2011 in the
non-endemic setting of Lyon, France. Study site was the
Parasitology Department of the Lyon University Hospital,
were symptomatic travellers, returning from malaria en-
demic countries, are routinely checked for malaria. Blood
samples were collected from febrile patients suspected of
malaria due to recent history of travel abroad. Malaria
diagnosis was carried out with Giemsa-stained thick andthin blood smears and real time PCR was performed as
previously described [15]. No specific blood samples were
collected for the RDT study, and data obtained with RDTs
were not used for the diagnosis or treatment of patients.
Study design in Bamako
The second part of the study was conducted between
July and December 2011, in a level two general health
centre (Centre de Santé de Référence de la commune
VI), where minimal laboratory equipment is available, in
the city of Bamako, Mali. This structure is located in a
district area of approximately 800,000 inhabitants, with
limited access to a higher level hospital facility. Malaria
is hyperendemic in the peripheral villages, mesoendemic
in the periurban area and hypoendemic in the city of
Bamako [16]. Malaria is transmitted between June and
December. This unstable transmission results in a non-
immune population and a risk for all age groups for mal-
arial disease. Plasmodium falciparum accounts for 95%
of all malaria infections at the country level. Inoculation
rates vary between 30 and 50 infective bites per human
per transmission season in the periurban area.
All patients presenting with a temperature >37.5°C
and with suspected malaria were included into the study
after informed consent was obtained. Exclusion criteria
were symptoms associated with signs of severe malaria
according to the definitions of the WHO [17], and ab-
sence of consent from the patient or parents. Local tech-
nicians collected finger-prick samples for thick and thin
blood films. The same finger-prick blood sample was
used to carry out the VIKIA Malaria Ag Pf/Pan™ and
CareStart™ RDTs. In addition, two drops of blood were
spotted onto filter paper, individually stored in a plastic
bag and sent to the Parasitology Department of the Lyon
University Hospital for PCR correction. In all cases the
diagnosis of malaria was confirmed or ruled out using
microscopic examination of blood smears. Only results
from microscopy were communicated to the patient and
medical doctor for subsequent treatment if necessary.
Data obtained from the two RDTs were not used for the
diagnosis of the current disease. For each participant
case report forms were completed, which were super-
vised by the local investigator, and controlled by the
principal investigator. All discrepancies were resolved by
consensus.
Microscopy
Thick and thin films were prepared on a single slide.
After thin films were fixed in methanol and air-dried,
slides were stained in 10% Giemsa solution for 15 min.
The parasitaemia was recorded as number of asexual
parasites counted per 200 white blood cells present in
the thick smear. The thick-film was considered to be
negative, if no parasite had been found in 100 fields at
Eibach et al. Malaria Journal 2013, 12:188 Page 3 of 7
http://www.malariajournal.com/content/12/1/1881,000 × magnification. All the thick and thin blood
smears were read immediately by two local investigators
in both sites, and secondly read by an expert at the
Parasitology Department of the Lyon University Hos-
pital, as a quality control. All microscopists were blinded
to the results of the RDTs.
Rapid diagnostic tests
The VIKIA Malaria Ag Pf/Pan™ test was performed by
medical or pharmaceutical students at the Lyon study
site, and by local community health workers at the
Bamako study site, immediately after the samples were
collected. The Lyon study site performed only the VIKIA
Malaria Ag Pf/Pan™ (IMAccess, Lyon, France) test, while
in Bamako the CareStart Malaria™ (AccessBio, USA), a
commonly used RDT in Mali, was used as an additional
control. Both tests were used according to manufac-
turer’s recommendation (lot numbers: RD_MA2_110527
(VIKIA Malaria Ag Pf/Pan™), G21MR (CareStart Malaria™)).
The VIKIA Malaria Ag Pf/Pan™ test was read at different
time points (15, 20, 30, 60 minutes), while the CareStart
Malaria™ test was read after 20 minutes as recommended.
Community health workers in Bamako and medical and
pharmaceutical students in Lyon were trained by the same
investigator to use both tests according to standard operat-
ing procedures. Each staff member was qualified for the
global study protocol and the specific SOPs before the start
of the study. An external quality monitoring in Bamako
was conducted twice during the study. Study quality
improvements were added to SOPs when deficiencies
were identified.
DNA extraction and amplification
All discordant results between microscopy and the two
RDTs were resolved by PCR and test characteristics were
recalculated according to the PCR-corrected results.
DNA of blood samples from the Lyon study site was
extracted using a spin-column procedure (Qiagen, Hilden,
Germany). DNA from blood spots on filter papers from
the Bamako study site was extracted using Instagene
Matrix resin™ (Bio-Rad, Marnes la Coquette, France) [15].
Species-specific primers targeting the 18s rRNA were used
to identify the parasite species, using LightCycler (Roche,
Switzerland) real-time PCR [15]. The real-time PCR was
submitted to a quality assurance process, including a pro-
ficiency panel provided by two independent laboratories,
twice a year.
Data analysis
The data collected were computerized using Excel pro-
gram (Microsoft, USA). Statistical analysis was performed
with Stata 12 (Statacorp, USA). Sensitivity was calculated
as the proportion of positive test results obtained among
samples containing malaria parasites as identified by PCR-corrected microscopy. Specificity was calculated as the
proportion of negative test results among samples nega-
tive in PCR-corrected microscopy. Positive and negative
predictive values were obtained by the proportion of true-
positive results among all positive samples and the
proportion of true negative results among all negative
samples, respectively. Sensitivity, specificity, positive and
negative predictive values were determined for both RDTs
at all reading time points. A 95% confidence interval
(95% CI) was given for each parameter. Samples with
mixed infections were not considered in the test per-
formance calculations. Proportions were compared using
the McNemar test with p-values <0.05 considered as being
significant.
Ethical approval
Permission to perform the study was obtained from the
Ministry of Health in Bamako, Mali. Informed written
consent was taken from all study participants and care-
givers of all children under 18 at the Bamako study site.
Results
155 patients were included at the Parasitology Depart-
ment of the Lyon University Hospital. PCR-corrected
microscopy revealed 69 (44.5%) malaria positive blood
samples. The majority of patients were of African ethnicity
(68%), 19 patients were Caucasian (28%) and the ethnicity
was unknown for three patients (4%). According to the in-
formation given by the patients, anti-malarial chemo-
prophylaxis was regularly taken by 32% (n=22). Most of
malaria infected travellers returned from West Africa
(n=54; 78%), followed by Central Africa (n=7; 10%), East
Africa (n=3; 4%), India (n=2; 3%), South-East Asia (n=2;
3%) and Central Asia (n=1; 1%). Plasmodium falciparum
was the most frequently detected species (n=49; 71%)
followed by Plasmodium ovale (n=9; 13%), Plasmodium
vivax (n=5; 7%) and Plasmodium malariae (n= 1; 1%).
Mixed infections were detected in five cases (7.0%). A
parasitaemia lower than 1,000 parasites/μl was observed
in 16 patients (23%), a high parasitaemia above 100,000
parasites/μl was detected in 5 patients (7%).
Plasmodium falciparum diagnosis was confirmed in
48/49 patients and for 5/5 patients with mixed infections
(Table 1), when reading the VIKIA Malaria Ag Pf/Pan™
after 30 minutes, giving a sensitivity of 98.0% (95% CI
87.8–99.9) (Table 2). Malaria diagnosis for non-falciparum
species was confirmed in 8/15 patients after 15 minutes,
increasing to 9/15 patients (sensitivity=60.0%; 95% CI
32.9–82.5; specificity=100%; 95% CI 96.6–100.0) when the
test was read between 20 and 60 minutes. For non-
falciparum species other than P. ovale the sensitivity
increases to 100% (95% CI 51.7–100.0). Four negative
samples and two P. ovale samples were false positive for P.
falciparum after 15 minutes, increasing to three P. ovale
Table 1 Results of the VIKIA Malaria Ag Pf/Pan™ RDT performed in Lyon
PCR-corrected microscopy species identification VIKIA Malaria Ag Pf/Pan™
15 minutes 20 minutes 30 minutes
Pf Pan Pf+Pan no Pf Pan Pf+Pan no Pf Pan Pf+Pan no
P. falcipatum (n=49) 11 0 36 2 11 0 36 2 12 0 36 1
P. vivax (n= 5) 0 4 0 1 0 5 0 0 0 5 0 0
P. ovale (n=9) 2 3 0 4 2 3 1 3 2 3 1 3
P. malariae (n=1) 0 1 0 0 0 1 0 0 0 1 0 0
P. ovale + P. falciparum (n=3) 0 0 3 0 0 0 3 0 0 0 3 0
P. malariae+ P. falciparum (n=2) 0 0 2 0 0 0 2 0 0 0 2 0
Negative (n=86) 2 0 2 82 2 0 2 82 2 0 2 82
Table 2 Diagnostic performances of the Care start™ and
VIKIA Malaria Ag Pf/Pan™ test (reading time: 30 minutes)
for the detection of P. falciparum and non-falciparum
species in Lyon and Bamako
Care Start Malaria™ VIKIA Malaria Ag
Pf/Pan™










PPV % (95% CI) 87.3 100.0
(74.9–94.3) (62.9–100.0)





96.2 60.0 94.6 100
(90.8–98.6) (17.0–92.7) (88.8–97.6) (46.3–100.0)
Specificity %
(95% CI)
97.7 99.4 98.0 99.2
(96.0–98.7) (98.5–99.8) (96.4–98.9) (98.1–99.7)
PPV % (95% CI) 89.9 42.9 91.1 45.5
(83.4–94.2) (11.8–79.8) (84.7–95.1) (18.1–75.4)
NPV % (95% CI) 99.1 99.7 98.8 100.0
(97.9–99.7) (98.9–100.0) (97.5–99.5) (99.3–100.0)
PPV positive predictive value, NPV negative predictive value, Pf P. falciparum,
non-Pf Plasmodium non-falciparum.
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negative results for all Plasmodium species decreased
from seven to four when readings were performed at 15
and 30 minutes respectively. The test results did not differ
regarding the level of parasitaemia. Differences between
the VIKIA Malaria Ag Pf/Pan™ and corrected microscopy
were not significant for the detection of P. falciparum
(p=0.07), but significant for the detection of non-falciparum
species (p=0.03).
At the “Centre de santé de reference de la commune
VI” of Bamako, 727 patients were included during the
study period. The mean age was 23.5 ± 14.9 (median=21,
range 1–60) and the mean body temperature was 37.8°C
(Table 3). More than 90% of the patients indicated, that
they received traditional or registered drugs, including
antipyretics, anti-malarials and antibiotics before arriving
to the health post. However, since patients’ knowledge
about drugs and diseases is considered low, data col-
lected during medical consultation were subject to cau-
tion. For patients, who were treated before admission,
the quality of drugs, the dosage and the duration of
treatment remained unknown.
135/727 (18.6%) patients were positive for malaria
parasites according to PCR-corrected microscopy of
thick and thin blood smears (Table 4). None of them
presented clinical signs of severity. Among the 135 mal-
aria patients, mean blood parasitaemia at admission was
3490 ± 18950 parasites/μl (median=3250). 130 patients
(96.3%) presented with P. falciparum malaria, three pa-
tients (2.2%) with P. ovale and two patients (1.5%) with
P. malariae. Differences in the mean age between mal-
aria and none-malaria patients was not significant
(p<0.05). The mean body temperature at admission was
higher in malaria patients than in non-malaria patients
(38.8 ± 2.8 vs. 37.5 ± 1.3, respectively, (p<0.05).
Malaria diagnosis (for all species) was confirmed in
128/135 patients in both the CARE-START Malaria™
and VIKIA Malaria Ag Pf/Pan™ test after a 30 minutes
reading time (Table 4). Plasmodium falciparum diagno-
sis was confirmed in 125/130 (sensitivity=96.2%; 95% CI90.8–98.6) and 123/130 (sensitivity=94.6%; 95% CI 88.8–
97.6) patients using the CARE-START Malaria™ and
VIKIA Malaria Ag Pf/Pan™ test respectively (Table 2).
For non-falciparum species the CARE-START Malaria™
identified 3/5 patients (sensitivity=60.0%; 95% CI 17.0–
92.7) correctly, while the VIKIA Malaria Ag Pf/Pan™
identified 4/5 patients after 15 minutes and 5/5 patients
(sensitivity=100.0%; 95% CI 46.3–100.0) after 30 minutes
reading time. Considering the low number of non-
Table 3 Study population in Bamako, Mali
Included Malaria Non-malaria
Number of patients 727 127 600
Mean age ± Standard deviation 23.5 ± 14.9 20.3 ± 18.5 24.2 ± 13.9
Median age 21 17 21
Mean temperature ± Standard
deviation (°C)
37.8 ± 1.7 38.8 ± 2.8 37.5 ± 1.3
Median temperature 37.6 39 37.5
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finitive conclusion can be drawn from these results.
The CARE-START Malaria™ test produced 18 false
positive and 7 false negative results for all Plasmodium
species. Similarly, 18 false positive results and 8 false
negative results after 15 minutes, decreasing to seven
false negative results between 30 and 60 minutes, were
obtained from the VIKIA Malaria Ag Pf/Pan™ test. For
both tests the number of false negative decreased to
three for a parasitaemia >200 parasites/μL and to zero
when parasitaemia was >1000 parasites/μL.
No significant difference in the detection of falciparum
(p=0.13) and non-falciparum (p=0.5) Malaria between
the two RDTs was observed. The performance of the
VIKIA Malaria Ag Pf/Pan™ test was not significantly dif-
ferent for P. falciparum (p=0.4), but for non-falciparum
species (p=0.03) compared to PCR-corrected microscopy
method.
Local staffs, with limited laboratory skills, were easily
trained to the use of the VIKIA Malaria Ag Pf/Pan™. No
difficulties in tests readings were noted. Tests were
stored at room temperature during the study period,
without detected alteration; however no specific study
was conducted on the test stability. Technical instruc-
tions, provided with the tests, were considered to be
clear and explicit for performing the test by local users.
Discussion
The new VIKIA Malaria Ag Pf/Pan™ RDT showed sensi-
tivities above 94% in Mali and 98% in France with speci-
ficities above 93% for the detection of P. falciparum
malaria in endemic as well as in non-endemic settings
and fulfils the requirements for a useful RDT, according
to WHO standards. The test performance is comparableTable 4 Results of the Care start™ and the VIKIA Malaria Ag P
PCR-corrected microscopy species identification Care start™ Mala
20 minutes
Pf Pan Pf+Pan
P. falciparum (n=130) 29 0 96
P. ovale (n=3) 0 2 0
P. malariae (n=2) 0 1 0
Negative (n=592) 13 4 1to the commonly used CARE-START Malaria™ RDT. At
the Lyon and the Bamako sites, the test showed similar
results as the PCR-corrected microscopy for P. falcip-
arum detection. The best reading time is between 20 and
30 minutes, and should not be reduced to 15 minutes in
order to limit false negative results. Similar results with the
VIKIA Malaria Ag Pf/Pan™ were obtained from a study in
Cambodia, showing a sensitivity of 93.4% and a specificity
of 98.6% for falciparum malaria [14].
A meta-analysis calculated a mean sensitivity and spe-
cificity of 95.0% and 95.2% respectively for HRP-2 based
assays [18]. However comparison between published
RDT trial reports is difficult due to differences in guide-
lines, the study population, parasitaemia levels, reference
techniques and quality of RDTs after exposure to high
temperatures, high humidity or substandard transport
and storage conditions.
In Bamako, the study was performed under field condi-
tions, carried out by non-expert community health workers.
The conditions were representative for a typical medical
reference centre in low-income countries; therefore, the
data obtained with both RDTs for malaria diagnosis were
entirely satisfactory.
It is known that a small number of P. falciparum
parasites show deletions or mutations of the hrp-2 gene,
leading to false negative results with RDTs [19,20]. The
hrp-2 expression in false negative samples was not
tested, thus the possibility that these parasites are re-
sponsible for some false negative results cannot be ex-
cluded. It has as well been suggested that anti-hrp-2
antibodies in humans may explain negative test results
despite significant parasitaemia [21].
A reduced sensitivity for non-falciparum species in
combined hrp-2/aldolase RDTs has been noticed in
many studies [22-24], with minimal data regarding
the ability of RDTs to detect P. ovale, P. malariae or
even Plasmodium knowlesi. Considering the low num-
ber of samples with non-falciparum malaria at both
study sites, statistically valid knowledge has not been
obtained.
This study confirms previous abundant literature
showing that RDTs are not able to replace microscopy
as the gold standard for malaria diagnosis in most cases.
However, RDTs have a justified place in laboratories off/Pan™ RDT in Bamako
ria VIKIA Malaria Ag Pf/Pan™
15 minutes 20 minutes
no Pf Pan Pf+Pan no Pf Pan Pf+Pan no
5 30 0 93 7 30 0 93 7
1 0 3 0 0 0 3 0 0
1 0 1 0 1 0 1 0 1
574 10 6 2 574 10 6 2 574
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lenges faced in non-endemic regions are a low parasite
density, altered parasite morphology due to the use of
chemoprophylaxis or empiric therapy and inexperience
in identifying malaria parasites due to the small number
of cases seen [25]. Those problems are illustrated in the
high failure rate of 11.2% for the identification of P. fal-
ciparum in U.S. laboratories [8], and failure rates of 27%
and 21% in Canadian and British laboratories respectively
[7,9]. Therefore, RDTs can be used complementary in
non-endemic countries in situation where experienced
personnel is not available, in order to perform a rapid
diagnosis, which can few hours later be confirmed or
corrected by microscopy or PCR.
In malaria endemic countries, RDTs may contribute to
rationalization of treatment of febrile illness and reduce
anti-malarial drug consumption in areas where microscopy
diagnosis is not available, not reliable or not performed
immediately. Successful use of RDTs can be observed in
Zambia, where the consumption of artemisinin-based
combination therapy could be reduced as a result [26].
Conclusion
VIKIA Malaria Ag Pf/Pan™ showed a similar level of
performance than comparative RDTs in endemic and in
non-endemic settings. Community health workers were
as efficient as medical students in managing malaria
cases using both RDTs tested. This new RDT, recently
commercially available, could be used to implement
efficient malaria diagnosis in low-income endemic
countries or complement PCR/microscopy diagnosis in
non-endemic regions.
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